BioCentury
ARTICLE | Finance

No easy way up

Why execution could be only way for Allergan to turn its stock around

June 16, 2018 1:12 AM UTC

A prolonged period of underperformance at Allergan plc (NYSE:AGN) has activists agitating for change, but there likely aren’t any quick fixes.

Looming competition and IP setbacks for key franchises, a mixed business development record and a handful of quarterly misses have plagued the company over the past three years, crushing investor sentiment and its shares...

BCIQ Company Profiles

Allergan plc

Pfizer Inc.